Rockefeller Capital Management
SYRE icon

Rockefeller Capital Management’s Spyre Therapeutics SYRE Stock Holding History

Rockefeller Capital Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.23M Buy
64,002
+63,453
+11,558% +$2.39M 0.01% 1095
2025
Q4 		$18K Buy
549
+148
+37% +$3.87K ﹤0.01% 3560
2025
Q3 		$6.72K Buy
+401
New +$6.54K ﹤0.01% 3785

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Rockefeller Capital Management's SYRE Position: Q1 2026 in Review

Rockefeller Capital Management increased its Spyre Therapeutics (SYRE) stake by 11,558% in Q1 2026, buying an estimated $2.39M and bringing the position to 64,002 shares worth $3.23M. The position accounts for 0.01% of the portfolio, ranked #1095.

Rockefeller Capital Management first reported a position in SYRE in Q3 2025 and has held it in 3 quarters since. 197 funds tracked by Wall St. Rank hold SYRE as of Q1 2026.

  • Rockefeller Capital Management held 64,002 shares of Spyre Therapeutics worth $3.23M as of Q1 2026.
  • Rockefeller Capital Management bought 63,453 Spyre Therapeutics shares in Q1 2026, an estimated $2.39M.
  • Spyre Therapeutics made up 0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #1095 holding.
  • Rockefeller Capital Management first reported a position in Spyre Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 197 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.